<DOC>
	<DOCNO>NCT02888327</DOCNO>
	<brief_summary>This open-label , four group , fixed-sequence study evaluate safety pharmacokinetic interaction AL-794 oseltamivir , JNJ-63623872 ( formerly VX-787 ) probe P-glycoprotein , CYP3A OATP1B1 healthy volunteer .</brief_summary>
	<brief_title>A Drug-Drug Interaction Study Evaluate Effect AL-794 Pharmacokinetics Oseltamivir JNJ-63623872</brief_title>
	<detailed_description>This open-label , four group , fixed-sequence study evaluate safety pharmacokinetic interaction AL-794 oseltamivir , JNJ-63623872 ( formerly VX-787 ) probe P-glycoprotein , CYP3A OATP1B1 healthy volunteer . For group , study consist eligibility screen period , study period , 1 follow-up visit . Groups may enroll parallel subject enrol one group may participate another group .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>1 . Subject provide write consent . 2 . In investigator 's opinion , subject able understand comply protocol requirement , instruction , protocolstated restriction likely complete study plan . 3 . Subject good health deem investigator , base finding medical evaluation include medical history , physical examination , laboratory test , electrocardiogram ( ECG ) . 4 . Male female , 1860 year age . 5 . Body mass index ( BMI ) 1830 kg/m2 , inclusive . The minimum weight 50 kg . 6 . A female subject eligible participate study nonchildbearing potential ( defined female document tubal ligation , bilateral oophorectomy hysterectomy ) postmenopausal ( defined 12 month spontaneous amenorrhea follicle stimulate hormone level within laboratory 's reference range postmenopausal female ) . A postmenopausal female receive hormone replacement therapy willing discontinue hormone therapy 28 day study drug dose agrees remain hormone replacement therapy duration study may eligible study participation . Females must refrain donate egg ( ovum , oocytes ) purpose assist reproduction checkin 6 month dose . 7 . If male , subject surgically sterile practice acceptable form birth control 90 day end study . Males must agree refrain sperm donation checkin 90 day dose . 1 . Men whose female partner pregnant contemplate pregnancy date screen 90 day last dose study drug . 2 . Clinically significant laboratory abnormality abnormality deem interfere ability interpret study data . 3 . Creatinine clearance le 60 mL/min ( MDRD ) . 4 . Total bilirubin , ALT , AST , alkaline phosphatase &gt; 1.2Ã— upper limit normal ( documented Gilbert 's permit ) . 5 . Clinically significant cardiovascular , respiratory , renal , gastrointestinal , hematologic , neurologic , thyroid medical illness psychiatric disorder , determine Investigator and/or Sponsor 's Medical Monitor . 6 . Positive screen test influenza , hepatitis A , B , C human immunodeficiency virus ( HIV ) serology . 7 . Any condition , opinion investigator , would compromise study 's objective wellbeing subject prevent subject meeting study requirement . 8 . Participation investigational drug trial receive investigational vaccine within 3 month 5 halflives ( whichever longer ) prior study medication . 9 . Clinically significant abnormal ECG finding . Particularly , history family history prolong QT syndrome ( eg , torsade de pointes ) , preexist sinus node disease , ( incomplete ) AV block , heart failure , sudden cardiac death ; correct QT interval ( QTcF QTcB ) &gt; 450 millisecond male subject &gt; 470 millisecond female subject screen visit . 10 . Clinically significant blood loss elective blood donation significant volume ( ie , &gt; 500 mL ) within 90 day first dose study drug ; &gt; 1 unit plasma within 7 day first dose study drug . 11 . Clinically significant abnormal heart rate , respiratory rate , temperature blood pressure value outside normal range , per local standard ( evaluated semirecumbent recumbent position 5 minute rest ) consider clinically significant . One repeat measurement additional 5 minute rest permit one visit day . 12 . Evidence current diagnosis sleep apnea . 13 . Evidence clinically significant infection within 2 week prior admission . 14 . Unwilling abstain alcohol least 1 week prior start dose Study Completion visit . 15 . History regular alcohol intake &gt; 14 unit per week alcohol female &gt; 21 unit per week male ( one unit define 8 g alcohol ) within 3 month screen visit . 16 . History drug alcohol abuse accord Diagnostic Statistical Manual Mental Disorders ( 5th edition ) ( DSMV ) criterion within 1 year screen positive test result ( ) alcohol and/or drug abuse ( barbiturate , opiate , cocaine , cannabinoids , amphetamine , benzodiazepine ) screen Day 1 . 17 . History tobacco use use nicotinecontaining product within 3 month screen visit . 18 . The subject positive prestudy drug screen . 19 . The use concomitant medication , include prescription , counter medication , herbal medication , inducer inhibitor CYP enzymes , glucuronidation drug transporter ( include Pglycoprotein OATP1B1 ) within 14 day 5 halflives ( whichever longer ) prior first dose study medication exclude , unless approve Sponsor 's Medical Monitor . Occasional use paracetamol , equivalent , permit . 20 . Exposure 4 new investigational entity within 12 month prior first dose day . 21 . Hypersensitivity active substance excipients AL794 , oseltamivir , JNJ63623872 , digoxin , midazolam , pitavastatin . 22 . Unwillingness inability comply study protocol reason . 23 . Employee investigator study center , direct involvement propose study study direction investigator study center , well family member employee investigator employee Johnson &amp; Johnson .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>